Literature DB >> 21465242

Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia.

Tamara Romón1, Guadalupe Mengod, Albert Adell.   

Abstract

RATIONALE: A reduction of GABAergic markers in postmortem tissue is consistently found in schizophrenia. This is generally mediated by a decreased expression of the calcium-binding protein, parvalbumin (PV), and the 67-kDa isoform of the GABA synthesizing enzyme glutamic acid decarboxylase (GAD(67)). Similar reductions of PV or GAD(67) are observed after repeated exposure to N-methyl-D-aspartate (NMDA) receptor antagonists but less attention has been paid to what occurs after their acute administration.
OBJECTIVES: Here, we have used in situ hybridization to examine the expression of PV and GAD(67) mRNAs at 4 h and 24 h after an acute administration of MK-801 (1 mg/kg).
RESULTS: Four hours after MK-801, the expression of PV mRNA decreased only in dentate gyrus of the hippocampus. Twenty four hours after this treatment, a reduction of the levels of PV mRNA was found in the medial prefrontal, orbitofrontal and entorhinal cortices, hippocampus and the basolateral nucleus of the amygdala. In contrast, no changes in the expression of GAD(67) were observed in any of the brain regions examined. Interestingly, the reduction in PV mRNA expression is observed in discrete corticolimbic subregions that have been implicated in schizophrenia, which is coincident with changes observed in postmortem tissue of schizophrenia brain.
CONCLUSIONS: These findings indicate that acute administration of a NMDA antagonist delineate a pattern of changes in GABAergic markers different from those observed in postmortem tissue in schizophrenia inasmuch as only deficits in parvalbumin (but not GAD(67)) were seen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465242     DOI: 10.1007/s00213-011-2268-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders.

Authors:  Schahram Akbarian; Hsien-Sung Huang
Journal:  Brain Res Rev       Date:  2006-06-08

3.  Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.

Authors:  Raymond Y Cho; Judith M Ford; John H Krystal; Marc Laruelle; Bruce Cuthbert; Cameron S Carter
Journal:  Schizophr Bull       Date:  2005-09-15       Impact factor: 9.306

Review 4.  Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks.

Authors:  Marlene Bartos; Imre Vida; Peter Jonas
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

5.  NMDA-dependent modulation of CA1 local circuit inhibition.

Authors:  H C Grunze; D G Rainnie; M E Hasselmo; E Barkai; E F Hearn; R W McCarley; R W Greene
Journal:  J Neurosci       Date:  1996-03-15       Impact factor: 6.167

Review 6.  Two isoforms of glutamate decarboxylase: why?

Authors:  J J Soghomonian; D L Martin
Journal:  Trends Pharmacol Sci       Date:  1998-12       Impact factor: 14.819

7.  Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding.

Authors:  M Pompeiano; J M Palacios; G Mengod
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

8.  NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex.

Authors:  Mark E Jackson; Houman Homayoun; Bita Moghaddam
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

9.  Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain.

Authors:  M S Todtenkopf; F M Benes
Journal:  Synapse       Date:  1998-08       Impact factor: 2.562

10.  Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex.

Authors:  Bret A Morrow; John D Elsworth; Robert H Roth
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.415

View more
  12 in total

1.  NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia.

Authors:  John A Saunders; Michael J Gandal; Steve J Siegel
Journal:  Neurobiol Dis       Date:  2012-01-09       Impact factor: 5.996

2.  Is the acute NMDA receptor hypofunction a valid model of schizophrenia?

Authors:  Albert Adell; Laura Jiménez-Sánchez; Xavier López-Gil; Tamara Romón
Journal:  Schizophr Bull       Date:  2011-09-28       Impact factor: 9.306

Review 3.  The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia.

Authors:  Diana C Rotaru; David A Lewis; Guillermo Gonzalez-Burgos
Journal:  Rev Neurosci       Date:  2012-01-09       Impact factor: 4.353

Review 4.  Synapse-specific contributions in the cortical pathology of schizophrenia.

Authors:  Saurav Seshadri; Mariela Zeledon; Akira Sawa
Journal:  Neurobiol Dis       Date:  2013-01-18       Impact factor: 5.996

5.  Aripiprazole differentially regulates the expression of Gad67 and γ-aminobutyric acid transporters in rat brain.

Authors:  Nina Peselmann; Andrea Schmitt; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-12       Impact factor: 5.270

Review 6.  Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.

Authors:  Mathias Zink; Susanne Englisch; Andrea Schmitt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-12       Impact factor: 5.270

7.  Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-03       Impact factor: 5.176

8.  PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis.

Authors:  V Wiescholleck; D Manahan-Vaughan
Journal:  Transl Psychiatry       Date:  2012-03-13       Impact factor: 6.222

9.  MK-801 Impairs Cognitive Coordination on a Rotating Arena (Carousel) and Contextual Specificity of Hippocampal Immediate-Early Gene Expression in a Rat Model of Psychosis.

Authors:  Stěpán Kubík; Helena Buchtová; Karel Valeš; Aleš Stuchlík
Journal:  Front Behav Neurosci       Date:  2014-03-12       Impact factor: 3.558

10.  Crybb2 coding for βB2-crystallin affects sensorimotor gating and hippocampal function.

Authors:  Minxuan Sun; Sabine M Hölter; Jens Stepan; Lillian Garrett; Just Genius; Elisabeth Kremmer; Martin Hrabě de Angelis; Wolfgang Wurst; D Chichung Lie; Laure Bally-Cuif; Matthias Eder; Dan Rujescu; Jochen Graw
Journal:  Mamm Genome       Date:  2013-10-06       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.